In addition, a genome-wide CRISPR-Cas9 screen by Hayman et al. revealed that STING acts as a regulator of ROS homeostasis that deletion of STING leads to enhanced cellular ROS metabolism and therapeutic resistance to DNA damaging agents in head and neck squamous cell carcinoma, and that pharmacological activation of STING enhances the anti-tumor effects of IR in vivo. Here, STING1 is linked to neoplasm.